Famotidine
From Wikipedia, the free encyclopedia
 |
|
|
Famotidine
|
|
| Systematic (IUPAC) name | |
| 2-[4-[2-(amino-sulfamoylimino-methyl) ethylsulfanylmethyl]-1,3-thiazol-2-yl]guanidine |
|
| Identifiers | |
| CAS number | |
| ATC code | A02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C8H15N7O2S3 |
| Mol. mass | 337.449 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 20–66% |
| Protein binding | 10–28% |
| Metabolism | hepatic-less than 30% |
| Half life | 2.5-4 hours (clinical half-life 8-12 hours) |
| Excretion | Principally excreted unchanged in urine |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. | |
| Legal status |
S3/S4 (Au), POM/OTC (UK), |
| Routes | Oral, IV |
Famotidine (INN) (IPA: [fəˈmɒtɪdin]) is a histamine H2-receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). It is commonly marketed by Merck under the trade names Pepcidine and Pepcid.
[edit] Clinical use
Main article: H2-receptor antagonist
Certain preparations of famotidine are available over the counter (OTC) in various countries. In the United States, preparations of 10 mg and 20 mg tablets, sometimes in combination with a more traditional antacid, are available OTC. Larger doses still require a prescription.
[edit] History and development
Famotidine was developed by Merck & Co.. The imidazole-ring of cimetidine was replaced with a 2-guanidinothiazole ring. Famotidine proved to be 30 times more active than cimetidine.
It was first marketed in 1985. Pepcid RPD orally-disintegrating tablets (that are not swallowed) was released in 1999. Generic preparations became available in 2001, e.g. Fluxid (Schwarz). In the United States, a product called Pepcid Complete is available that combines famotidine with an antacid in a chewable tablet to ameliorate the relatively slow onset of effects.
Cimetidine, Famotidine, Nizatidine, Ranitidine, Roxatidine
